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Oral Presentations 
the major risk factor for relapse in 69 ALL patients (0.89 and 0.59 
for those transplanted in relapse and in CR &#61619; II, respec- 
tively; 0.00 in CR i). Lack of an NK-cell alloreactive donor was 
the major risk factor for relapse in 76 AIML patients (0.12 for 
recipients of NK-alloreactive donors vs 0.68 for the others). In the 
109 patients who received the fludarabine-modified conditioning 
regimen and immunoselected CD34+ cells primary engraftment 
improved fi'om the 80% of our original series of 36 patients to the 
current 94%. Incidence of severe GvHD dropped from 18% to 
7%. 65/109 patients received fludarabine in the conditioning, 
Clinimacs-selected CD34+ cells and no G-CSF post-transplant. 
Immune recovery improved. The clinical impact was most marked 
in AML patients transplanted in a W remission. The probability of 
infection-related mortality was 0.18 in these 26 patients vs 0.70 in 
15 patients at the same stage of disease who received Ceprate- 
treated grafts and G-CSF post-transplant. 38/65 patients were 
transplanted in remission and the 3 year probability of EFS is 0.60 
and 0.40 for the 19 AML and 19 ALl,, respectively. 
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AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PRIMARY 
SYSTEMIC AMYLOIDOSIS (AL): THE IMPACT OF SELECTION CRITERIA 
ON OUTCOME 
3/[ollee, P.; ~'Vechaleka1", A.; Pereira, D.; Franke, N.; Reece, D.; 
Che~, C.; Stewa:'t, A. Princess Margaret Hospital, To*'o*~to, ON, 
Gmada. 
Introduction: ASCT has produced higher response rates than 
conventional chemotherapy in patients (pts) with AL. However, 
transplant-related mortality (TRM) remains high and reported 
series are subject o selection bias. Methods: We report a retro- 
spective analysis of all pts with symptomatic AL referred to onr 
center from '96-'01, identifying prognostic variables and the 
impact of ASCT in the entire population. Results: 48 pts had pri- 
mary AL: median age 58 yrs; median time from diagnosis to refer- 
ral 1.Smonths; and prior therapy in 27%. Organ involvement: 
renal 68%; cardiac 77%; liver 42%; and neurologic 19%. The 26 
pts who were deemed ASCT candidates were younger (55 vs 63 
yrs, p=0.001), had a better performance status (96% vs 73% with 
ECOG score -<2, p=0.02) and a trend to a better left ventricular 
ejection traction (27% vs 45% with EF <50%, p=0.2) and less syn- 
cope (4% vs 18%, p=0.11). Five pts died during the peri collec- 
tion period from progressive disease oi- mobilization complica- 
tions and one failed to mobilize stem cells. 20 pts underwent 
ASCT following high-dose melphalan. TRM was 35%; however, 
since Jan'99 TRM has fallen from 50% to 20%. Intent-to-treat 
organ responses were: renal 46%, cardiac 25% and liver 50%. 
The 3yr OS post-ASCT was 56% with improved outcome pre- 
dicted by a better performance status (p=0.08), normal ALP 
(p=0.08), nephrotic syndrome (p=0.0l) and absence of severe 
hypotension (3yr OS 0% vs 75% for systolic BP<vs>90mmItg, 
p<0.001). The 3yrOS for all 48 referred pts (i.e.whether t ans- 
planted or not) was 44%, and this was not significantly" better for 
transplant candidates. Improved outcomes for all referred pts were 
associated with good ECOG performance status (<2 vs >2, 
p=0.001), the presence of nephr'otic syndrome (p=0.06), no 
increase in septal wall thickness (p=0.07) and a systolic 
BP>90mmHg (p<0.001). Conclusions: Selection of appropriate 
candidates for transplantation f primary AL is important and can 
resnlt in avoidance of excessive TRM. Those with systolic 
BP_<90mmHg and poor performance status (ECOG >2) have an 
exceedingly high mortality and should not be transplanted. For 
those undergoing ASCT, organ response rates appear promising, 
but overall only small numbers benefit. Conclusive evidence of 
improved survival for this select group of pts is still lacking and 
will require randomized trials. 
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HIGH INCIDENCE OF EPSTEIN-BARR VIRUS LYMPHOPROLIFERATIVE 
DISEASE (EBV-LPD) AFTER CD34-SELECTED AUTOLOGOUS PERIPH- 
ERAL BLOOD STEM CELL TRANSPLANT (PBSCT) IN CHILDREN WITH 
NEUROBLASTOMA(NB) 
Gr~:pp, S. ~; Powell, ff.~; Gr!(fin, G.~; Callahan, C.1, Aplenc, R. ~, B:mi~, 
N.J. j 1. C,~ildreT~s Hospital, Philadelphia, PA; 2. AI Dupont, ~l/7lm- 
kagton, DE. 
EBV-LPD is a disorder anging from a polyclonal B-cell lym- 
phoproliferation to lyn~phoma. It occurs as a result of inmmno- 
suppression and after allogeneic BMT, especially in recipients of 
T cell depleted grafts. EBV-LPD after autologous transplant is
uncommon. We describe an unnsually high incidence of EBV- 
LPD in children undergoing tandem high dose chemotherapy 
supported with CD34 selected peripheral blood stem cells 
(CD34+PBSC). 156 patients were treated on one of two sinfilar 
tandem PBSCT protocols, CHP-594 or CHP-667 at 4 institu- 
tions over a period of 6 years. Both studies employ 5 cycle induc- 
tion therapy, followed by tandem autologons PBSCT. 28 pts were 
enrolled on CHP-667 and 128 on CHP-594, including 119 chil- 
dren with NB, 29 with Ewing sarcoma nd 8 with other sarcomas. 
108/156 patients received CD34+PBSC, with 48 receiving unse- 
lected PBSC. CD34 selection was performed with 2 devices: 
Ceprate (n=26) and Isolex (n=82). Average dose of CD34 selected 
cells infused to patients on CHP-594 was 7xl06/kg; average dose 
on CHP-667 was 8.7x106/kg. CD34+PBSC were given in 81/128 
CHP-594 patients; 27/28 patients on CHP-667 received 
CD34+PBSC. Five patients developed EBV-LPD for an overall 
incidence of 3.2%. Incidence on the two studies was 1.6% on 
CHP-594 and 10.7% in the limited number of patients on CHP- 
667 (p=.041). Median time to develop EBV-LPD after transplant 
was 3 months (range 1-5 months). All patients who contracted 
LPD were in the CD34 selected group and all had NB (p=NS). 
4/5 patients experienced a CR of their LPD to rituximab therapy; 
3/5 are cnrrently living (1 having died from LPD and 1 from NB), 
and are 28, 13, and 4 months post therapy for EBV LPD. We 
conclude that the incidence of EBV-LPD after this highly 
immunosuppressive tandem autologous PBSCT regimen is higher 
than expected. Tandem transplant is itself highly immunosuppres- 
sive. However, as all patients with LPD had received 
CD34+PBSC processed on the Nexell device, CD34 selection also 
may play a role in the development of EBV-LPD. The risk of con- 
comitant T cell depletion with CD34+PBSC in autologous 
PBSCT regimens must be carefully examined and balanced 
against he potential benefit of umor cell purging, or stem ceil 
engineering strategies must include a plan to retnrn T cells as well. 
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OPTIMAL USE OF PERIPHERAL CD34 COUNTS (PCD34) TO GUIDE 
LEUKAPHERESIS IN AUTOLOGOUS PERIPHERAL HEMATOPOIETIC 
STEM CELL TRANSPLANTATION (PHSCT) 
Griffins, D.L., Kiss, J.E.; Stam'zak, H.M.; Koch, E.K.; Yeager, A.M.; 
Dom~enhevg, A.D. Medich~e, University of Pittshm'gh, Pittsbm'gh, PA. 
The ability to monitor PCD34 counts has the potential to gmide 
PHSCT collection after mobilization. Attempting to collect stem 
ceils when mobilization is insufficient is expensive and results in 
unnecessary isk and inconvenience for the patient. We measured 
PCD34 counts in a series of 123 recipients of autologous PHSCT. 
Absolute CD34 count was measured using Beckman-Coulter 
StemKit, modified to determine CD34 viability by 7-aminoactino- 
mycin-D exclusion (Donnenberg et al, Cytotherapy 2002). Test 
,result urnover was approximately 70 minutes fro m sample acces- 
sion to reporting. In the present test se , the decision to collect 
was based solely on WBC performed aily following mobilization 
(G-CSF +/- chemo). Patients reported *'or leukapheresis and 
CD34 testing when their WBC was greater than or equal to 2, 
500 cells/microliter. Patients who did not reach their collection 
goal (2-5 x 10E6 CD34/kg) after the initial leukapheresis were 
called back for additional leukaphereses (up to 4). To determine 
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how weI1 peripheral counts predicted CD34 recovery during the 
first collection, linear regression was performed using WBC, 
platelet (Ph) count, and PCD34 count as independent variables. 
Data were log transformed. WBC and Plt both were correlated 
with CD34 yield (p of slope = 0.000 and 0.012, respectively). 
However, coefficients of correlation (r^2) were low (0.137 and 
O. 162) rendering these parameters of little value for predicting the 
behavior of the individual patient, in contrast, the correlation of 
CD34 yield and PCD34 count was stri~ng (rA2=0.958). Cross 
tabs analysis of PCD34 performed on the day of leukapheresis 
revealed that a cutoffof 10 PCD34/microliter gave a 92.6% prob- 
ability of collecting in a single leukapheresis, and a 98.8% proba- 
bility after 1 or more leukaphereses. We are using these data to 
construct an algorithm to schedule patients for leukapheresis, with 
particular attention to the difficult o mobilize patient. 
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ANTIGEN PRESENTING CELLS IN THE LIVER RECRUITE ACTIVATED 
ALLOGENEIC CDS+ T CELLS TO ELICIT HEPATIC GRAFT-VERSUS- 
HOST DISEASE 
ZhmTg, I( l; Shlomchik, D~D.:; Joe, G J; LoTtbo,ati11, JJ; Zhu, J. I; Gian- 
nola, D. ~ ; Enzerson, S.G. i 1. ~ledicine, University of PemT.~vlvania School 
of ~lediciJze, Philadelphia, PA; 2. ~}zle University, New Haven, CT. 
Graft-versus-host disease (GVHD) induced by donor T cells rec- 
og~aizing minor histcompatibility antigens (miHAs) primarily target 
specific organs uch as the liver, skin and intestine. YVe have previous- 
ly demonstrated that rapid activation donor T cells by host antigen 
presenting ceils (APCs) is ufficient o both activation and effector 
phases of acute GVHD. However, it is not well understood how 
these organs become the main targets of activated alloreactive T cells. 
In order to measure whether tissue resident APCs might play a criti- 
cal role in initiating the local development of acute GVHD, we selec- 
tively depleted host macrophages and DCs from the livers and 
spleens but not from the skin, peripheral lymph nodes (PLN), or 
mesenteric lymph nodes (MLN) of C57BL/6 (B6) mice by intra- 
venous administration f liposomal-ehlodronate prior to allogeneic 
bone marrow transplantation. Depletion of host hepatic and splenic 
macrophages and DCs significantly inhibited the proliferation of 
donor C3H.SW CDS+ T cells in the spleen but not in the PLN or 
MLN of B6 mice. Such organ-selective depletion of host tissue APCs 
also markedly reduced the trafficking of allogeneic CD8+ T cells into 
the livers and spleens, but not PLN and MLN, of B6 recipients as 
compared to hat of the control mice. Acute hepatic, but not cnta- 
neous, GVHD was inhibited as well, resulting in improved survival of 
liposomal-chlodronate tr ated B6 recipients. YVhen C3H.SW 
CD8+T cells were activated in normal B6 recipients, recovered and 
adoptively transferred into secondary B6 recipients, activated onor 
CD8+ T cells rapidly migrated into the livers and spleens of control 
B6 recipients, but was markedly decreased in B6 mice that were 
depleted of hepatic and splenic macrophages and DCs. Interestingly, 
host APC activation of donor T cells induced the expression of 
CCR5 followed by CCR1 and CCR4. In contrast, CCR7 that is 
expressed on naive T cells was dramatically reduced on these activat- 
ed CD8+ T cells. Thus, tissue resident APCs control the local 
recnlitment of allo-reactive donor T cells and the subsequent devel- 
opment of acute GVHD via the coordinated expression of chemokine 
receptor CCR7, CCR5 and CCR1 on actiwlted onor CD8 T cells. 
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A PHASE I/ll STUDY OF RECOMBINANT HUMAN KERATINOCYTE 
GROWTH FACTOR (KGF) IN PATIENTS WITH HIGH RISK HEMATO- 
LOGIC MALIGNANCIES UNDERGOING MISMATCHED RELATED OR 
UNRELATED DONOR TRANSPLANT 
Reynolds, C.M.; Fe~v:nr< ft.; Raymond, H.; B'~vntn, T.; Ratamnha'natholv, 
U.; Aysh, L.; Levine, ft.; }~anik, G.; Cooke, R~; Silvel; S.; Redo!y, P.; 
Beckel; ?,I.; Ube~Ti, ft. Ulfiversitv of Michiglm, Ann A'rbol, MI. 
In murine BMT systems, the administration of KGF reduces 
small bowel damage and serum systemic inflammatory mediators 
resulting in less clinical GVHD while preserving GVL and 
improving leukemia free survival. We initiated aphase I/II, sched- 
ule escalation trial of KGF plus standard GVHD prophylaxis 
(tacrolimus and methotrexate) in patients with an unrelated or 
tILA mismatched donor who are therefore at high risk for devel- 
oping acute GVHD (AGVHD). All study patients (n=I 1) had high 
risk hematologic malignancies. Patients received a full-intensity 
conditioning regimen of CVB (cyclophosphamide, VP-16, 
BCNU), BAC (busulfan, cytarabine, cyclophosphamide) or 
CyTBI (cyclophosphamide, TBI 1200 cGy). KGF (60 mcg/kg/day 
intravenously) was administered for 3 consecutive days prior to 
the conditioning regimen, and then for 3 consecutive days each 
week starting Day 0, escalating in 2 week blocks. One DLT has 
been observed (CTC grade 3 skin rash on Day +6), One patient 
with progressive NHL prior to transplant received only 3 doses 
and was removed from the study, and a second patient with pri- 
mary refractory NHL died of sepsis within two weeks of trans- 
plant. Nine patients are fidly evaluable for AGVHD (table). All 
four patients receiving 6 doses of KGF developed AGVHD (one 
each with overall grades 1 to 4). Of five patients receiving either 
12 or 18 doses of KGF, one patient had grade 1 and one had grade 
2 AGVHD. Six patients are in remission at last follow-up. These 
preliminary results at the higher KGF doses compare fnvorably to 
historical controls in which the incidence of AGVHD is 50 to 
75% in patients receiving unrelated or HLA-mismatched allo- 
grafts. The study continues to accrue patients and will escalate the 
administration schedule of KGF up to 36 doses based on the inci- 
dence of DLTs. 
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SIROLIMUS (RAPAMYCIN) FOR TREATMENT OF STEROID-REFRACTO- 
RY CHRONIC GRAFT VERSUS HOST DISEASE 
Com'iel, D.R.; Hicks, 1C; Saliba, R.; Cohen, A.; It)politi, C.; Hsu, 1:; 
Donato, ~i.; Gi~vlt, S.; Khom'i, L; Hosing', C.; De LiTna, :~l.ff.; Ander- 
sson, B.; Gajewski, ft.; Ne~mzmm, ft.; CTJampliJl, R. Blood and 3/lmv'ozv 
Transplantation, UT ~ID Anderson Cancer Center, Hozzsron, TX. 
Chronic graft versus host disease (cGVHD) occnrs in approxi- 
mately 50% of patients following hematopoietic stem cell trans- 
plant. VVe conducted a phase II trial in 29 patients with steroid- 
refractory cGVHD (median age 42 years, range 18-69) utilizing 
tacrolimusin combination with sirolimns. At the time of sirolimus 
initiation, 20 patients (69%) had extensive cGVHD, and 9 
patients hinited. Disease sites included: lower GI tract (n=2), liver 
(n=6), skin (n=24), oral/vaginal mucosae (n=5), ocular (n=3), and 
upper GI tract (n=l). Eight patients had s~n involvement (30%) 
with scleroderma. The onset of eGVHD at study enrolhnent 
included 15 relapsing" (52%), 12 progressive (42%), and 2 (7%) de 
novo cases. All patients had failed multiple previous lines of 
immunosuppression (median 4, range 2-14) prior to sirolimus. 
Patients received sirolirnus uspension orally at a loading dose of 6 
rag, followed by a maintenance dose of 2 nag/day to maintain 
trough concentrations of 5-15 mg/dl. Additional monitoring 
inchided weekly lipid panels, }LMG CoA reductase inhibitors and 
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